Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-02-20 Merger & Acquisition
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by Eli Lilly and Company pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly to exchange shares of Elanco Animal Health Incorporated for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, pricing information, and references to a Prospectus. The document is not a full financial report but rather a communication related to a takeover bid or merger transaction. Rule 425 filings are typically used for merger communications and tender offers. Therefore, this document fits the category of Merger & Acquisition (MA) filings rather than a full Annual Report, Earnings Release, or other categories. The document length is substantial and contains detailed information about the exchange offer, consistent with an MA filing.
2019-02-20 English
M&A Activity 2019
M&A Activity Classification · 95% confidence The document is a detailed correspondence addressed to the U.S. Securities and Exchange Commission's Division of Corporation Finance, Office of Mergers and Acquisitions, regarding the pricing mechanism of an exchange offer by Eli Lilly and Company. It references SEC rules under the Exchange Act, discusses the mechanics and regulatory precedents of exchange offers, and compares the proposed pricing mechanism to similar past offers. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to a merger/acquisition transaction, specifically an exchange offer. The presence of references to Schedule TO-I (a tender offer filing) and detailed discussion of pricing mechanisms in the context of an exchange offer strongly indicates this is related to M&A activity. The document is substantive and not a brief announcement or certification, so it is not RNS or RPA. Therefore, the most appropriate classification is M&A Activity (Code: TAR).
2019-02-19 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Eli Lilly and Company. It is a shelf registration statement under the Securities Act of 1933, used to register securities for sale to the public. The document includes a prospectus describing the types of securities that may be offered, such as common stock, preferred stock, debt securities, warrants, etc. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2019-02-19 English
Eli Lilly and Company: Eli Lilly and Company Files 10-K
Report Publication Announcement Classification · 95% confidence The document is a short announcement stating that Eli Lilly and Company has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, with the SEC. It does not contain the actual report or financial data but informs shareholders about the filing and where to access the full report. The document length is only 1266 characters, which is quite short and fits the pattern of a report publication announcement rather than the full annual report itself. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA).
2019-02-19 English
10-K
Annual Report FY 2018
2019-02-19 English
425 Filing
M&A Activity Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly and Company to exchange shares of Elanco Animal Health Incorporated for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, and references to a prospectus and other related documents. The presence of Rule 425 filing and the detailed description of the exchange offer indicate this is related to merger and acquisition activity. The document is not a full annual or quarterly report, nor is it a simple announcement or proxy solicitation. It is a communication related to a takeover bid or merger transaction, fitting the M&A Activity category.
2019-02-19 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.